Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086606 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Xolair in Peanut Allergy
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00086606 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 150 participants.
The verdict
NCT00086606, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
Interventions
- DRUG Xolair (omalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086606
The ClinicalTrials.gov registry entry for NCT00086606 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xolair (omalizumab) is the first listed.
NCT00086606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086606 about?
NCT00086606 is a clinical study titled "A Safety and Efficacy Study of Xolair in Peanut Allergy". This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
What is the current status of trial NCT00086606?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-06. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00086606?
The interventions under investigation include: Xolair (omalizumab) (DRUG).
Who is sponsoring clinical trial NCT00086606?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.